Ocrelizumab (Ocrevus [Roche-Genentech]), a second-generation humanized anti-CD20 antibody, has been recently approved for multiple sclerosis (MS). Echoviruses and other enteroviruses have been associated with life-threatening infections in patients receiving anti-CD20 antibodies other than ocrelizumab.1-4 In this case study, we report a case of fulminant echovirus 25–associated hepatitis in a patient with relapsing-remitting MS who received ocrelizumab monotherapy.
Nicolini LA, Canepa P, Caligiuri P, et al. Fulminant Hepatitis Associated With Echovirus 25 During Treatment With Ocrelizumab for Multiple Sclerosis. JAMA Neurol. Published online April 08, 201976(7):866–867. doi:10.1001/jamaneurol.2019.0522
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: